EX-32.1 4 akro-20210331ex3213f7e66.htm EX-32.1

Exhibit 32.1*

​

CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

​

In connection with the Quarterly Report on Form 10-Q of Akero Therapeutics, Inc. (the “Company”) for the quarter ended March 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned hereby certify, pursuant to 18 U.S.C. Section 1350, that, to the best of their knowledge:

​

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

​

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

​

​ | ​
​ | /s/ ANDREW CHENG
​ | Andrew Cheng, M.D., Ph.D.
​ | President and Chief Executive Officer
​ | (Principal Executive Officer)

​

Dated: May 13, 2021

​

​ | ​
​ | /s/ WILLIAM WHITE
​ | William White
​ | Executive Vice President, Chief Financial Officer and Head of Corporate Development
​ | (Principal Financial and Accounting Officer)

​

Dated: May 13, 2021

​

​

* This certification shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934.